NCT05007860View on ClinicalTrials.gov

Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia

CompletedOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2023

Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
BIOLOGICAL

PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.

Vaccines administered per standard of care

Trial Locations (1)

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT05007860 - Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter